Questioning a Class Effect: Does ACE Inhibitor Tissue Penetration Influence the Degree of Fibrinolytic Balance Alteration following an Acute Myocardial Infarction?

Journal of Clinical Pharmacology

Volumn 44, Issue 2, 2004, Pages 150-157

  Tsikouris, James P ^a,b   Suarez, Jose A ^a   Meyerrose, Gary E ^a   Ziska, Martin ^a   Fike, David ^a   Smith, Jack ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b TEXAS TECH UNIVERSITY   (United States)

Author keywords

ACE inhibitor; Myocardial infarction; Plasminogen activator inhibitor

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; PLASMINOGEN ACTIVATOR INHIBITOR 1; QUINAPRIL; TISSUE PLASMINOGEN ACTIVATOR;

ACUTE HEART INFARCTION; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBRINOLYSIS; FOLLOW UP; HEART REINFARCTION; HUMAN; MALE; OPEN STUDY; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RISK BENEFIT ANALYSIS; TREATMENT OUTCOME;

ANALYSIS OF VARIANCE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ENALAPRIL; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PERMEABILITY; PLASMINOGEN ACTIVATOR INHIBITOR 1; TETRAHYDROISOQUINOLINES; TISSUE PLASMINOGEN ACTIVATOR;

EID: 1642576021     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270003262103     Document Type: Article

References (36)

1. Fuster V, Badimon L, Badimon JJ, et al: The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med 1992;326:310-318.
2. The Fourth International Study of Infarct Survival (ISIS-4) Collaborative Group: ISIS-4: a randomized factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58050 patients with suspected acute myocardial infarction. Lancet 1995;345:669-685.
3. Gruppo Italiano per lo Studio della Sopravivenza nell'infacto Miocardio: GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994;343:1115-1122.
4. Pfeffer MA, Braunwald E, Moye LA, et al, for the SAVE Investigators: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement trial. N Engl J Med 1992;327:669-677.
5. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators: Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342:821-828.
6. Kober L, Torp-Pedersen C, Carlsen JE, et al, for the Trandolapril Cardiac Evaluation (TRACE) Study Group: A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1995;333:1670-1676.
7. Brown NJ, Vaughn DE: Prothrombotic effects of angiotensin. Adv Intern Med 2000;45:419-429.
8. Hamsten A, de Faire U, Walldius G, et al: Plasminogen activator inhibitor in plasma: risk factor for recurrent MI. Lancet 1987;11:3-9.
9. Hamsten A, Wiman B, de Faire U, et al: Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of MI. N Engl J Med 1985;313:1557-1563.
10. Gram J, Jespersen J: A selection depression of tissue plasminogen activator (t-PA) activity in euglobulin characterizes a risk group among survivors of acute myocardial infarction. Thromb Haemost 1987;57:137-139.
11. Brown NJ, Agirbasli MA, Williams GH, et al: Effect of activation and inhibition of the renin-angiotensin system on plasma PAI-1. Hypertension 1998;32:965-971.
12. Vaughan DE, Rouleau J-L, Ridker PM, et al: Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction. Circulation 1997;96:442-447.
13. Jansson JH, Boman K, Nilsson TK: Enalapril related changes in the fibrinolytic system in survivors of myocardial infarction. Eur J Clin Pharmacol 1993;44:485-488.
14. Pederson OD, Gram J, Jeunemaitre X, et al: Does long-term angiotensin converting enzyme inhibition affect the concentration of tissue-type plasminogen activator-plasminogen activator inhibitor-1 in the blood of patients with a previous myocardial infarction? Coron Artery Dis 1997;8:283-291.
15. Moriyama Y, Ogawa H, Oshima S, et al: Relationship between serum angiotensin converting enzyme activity and plasma plasminogen activator inhibitor activity in patients with recent myocardial infarction. Coron Artery Dis 1998;9:691-696.
16. Wright RA, Flapan AD, Alberti GMM, et al: Effects of captopril therapy on endogenous fibrinolysis in men with recent myocardial infarction. J Am Coll Cardiol 1994;24:67-73.
17. Soejima H, Ogawa H, Yasue H, et al: Effects of imidapril therapy on endogenous fibrinolysis in patients with recent myocardial infarction. Clin Cardiol 1997;20:441-445.
18. Unger T, Ganten D, Lang RE, et al: Persistent tissue converting enzyme inhibition following chronic treatment with Hoe 498 and MK421 in spontaneously hypertensive rats. J Cardiovasc Pharmacol 1985;7:36-41.
19. Lyons D, Webster J, Benjamin N: Effect of enalapril and quinapril on forearm vascular ACE in man. Eur J Clinical Pharmacol 1997;51:373-378.
20. Hornig B, Arakawa N, Haussmann D, et al: Differential effects of quinaprilat and enalaprilat on endothelial function of conduit arteries in patients with chronic heart failure. Circulation 1998;98:2842-2848.
21. Fabris B, Jackson B, Cubela R, et al: Angiotensin converting enzyme in the rat heart: studies of its inhibition in vitro and ex vivo. Clin Exp Pharmacol Physiol 1989;16:309-313.
22. Nakijima T, Yamada T, Setoguchi M: Prolonged inhibition of local angiotensin-converting enzyme after single or repeated treatment with quinapril in spontaneously hypertensive rats. J Cardiovasc Pharm 1992;19:102-107.
23. Van Hinsberg VWM, Kooistra T, Emeis JJ, et al: Regulation of plasminogen activator production by endothelial cells: role in fibrinolysis and local proteolysis. Int J Radiat Biol 1991;60:261.
24. Kruithof EKO, Nicolosa G, Bachmann F: Plasminogen activator inhibitor 1: development of a radioimmunoassay and observations on its plasma concentration during venous occlusion and after platelet aggregation. Blood 1987;70:1645-1653.
25. Vaughan DE: The renin-angiotensin system and fibrinolysis. Am J Cardiol 1997;79:12-16.
26. Weishaar RE, Panek RL, Major TC, et al: Evidence from a functional tissue renin-angiotensin system in the rat mesenteric vasculature and its involvement in regulating blood pressure. J Pharmacol Exp Ther 1991;256:568-574.
27. Declerck PJ, Alessi MC, Verstreken M, et al: Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay. Blood 1988;71:220-225.
28. Rijken DC, Juhan-Vague I, de Cock F, Collen D: Measurement of human tissue-type plasminogen activator by a two-site immunoradiometric assay. J Lab Clin Med 1983;101:274-284.
29. Ranby M, Brandstrom A: Biological control of tissue plasminogen activator-mediated fibrinolysis. Enzyme 1988;40:130-143.
30. Bicket D: Using ACE inhibitors appropriately. Am Fam Physician 2002;66:461-468.
31. Drug Facts and Comparisons. 54th ed. St. Louis, MO: Wolters Kluwer, 2000.
32. Brown NJ, Gainer JV, Stein CM, et al: Bradykinin stimulates tissue plasminogen activator release in human vasculature. Hypertension 1999;33:1431-1435.
33. Goodfield N, Newby DE, Ludlam CA, et al: Effects of acute angiotensin II type 1 receptor antagonism and angiotensin converting enzyme inhibition on plasma fibrinolytic parameters in patients with heart failure. Circulation 1999;99:2983-2995.
34. Yusuf S, Sleight P, Pogue J, et al: Effects of an angiotensin converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-153.
35. Zuanetti G, Maggioni AP, Latini R, et al: The early beneficial effect of treatment with oral ACE-inhibitors in patients with acute MI [abstract]. Circulation 1995;92(Suppl. I):I-24.
36. Ryan TJ, Anderson JL, Antman TM, et al: 1999 update: ACC/AHA guidelines for the management of acute myocardial infarction: executive summary and recommendations. Circulation 1999;100:1016-1030.